Candel Therapeutics (NASDAQ:CADL) Trading Down 5.3%
Candel Therapeutics (NASDAQ:CADL) Trading Down 5.3%
Shares of Candel Therapeutics, Inc. (NASDAQ:CADL – Get Rating) fell 5.3% during mid-day trading on Wednesday . The company traded as low as $3.20 and last traded at $3.21. 6,148 shares were traded during trading, a decline of 82% from the average session volume of 33,482 shares. The stock had previously closed at $3.39.
坎德尔治疗公司(纳斯达克代码:CADL-GET评级)的股价在周三午盘交易中下跌5.3%。该公司股价低至3.20美元,最新报3.21美元。当日成交量为6,148股,较33,482股的平均日成交量下降82%。该股此前收盘价为3.39美元。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
Separately, Credit Suisse Group lowered their price objective on shares of Candel Therapeutics to $11.00 in a research report on Monday, August 15th.
另外,瑞士信贷集团在8月15日星期一的一份研究报告中将Candel治疗公司的股票目标价下调至11.00美元。
Candel Therapeutics Stock Down 5.3 %
Candel治疗公司股价下跌5.3%
The company has a debt-to-equity ratio of 0.34, a quick ratio of 14.86 and a current ratio of 14.86. The stock has a market capitalization of $92.74 million, a P/E ratio of -3.96 and a beta of 0.95. The stock's fifty day simple moving average is $3.41 and its two-hundred day simple moving average is $3.81.
该公司的负债权益比率为0.34,速动比率为14.86,流动比率为14.86。该股市值为9,274万美元,市盈率为-3.96,贝塔系数为0.95。该股的50日简单移动均线为3.41美元,200日简单移动均线为3.81美元。
Institutional Investors Weigh In On Candel Therapeutics
机构投资者看好Candel治疗公司
Candel Therapeutics Company Profile
坎德尔治疗公司简介
(Get Rating)
(获取评级)
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
Candel Treateutics,Inc.是一家临床阶段的生物制药公司,致力于为癌症患者开发免疫疗法。该公司开发了CAN-2409,这是治疗胰腺癌的第二阶段临床试验;治疗前列腺癌的第三阶段临床试验;以及治疗肺癌的第二阶段临床试验,以及治疗高级别胶质瘤的Ib/II阶段临床试验。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Candel Therapeutics (CADL)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
- 免费获取StockNews.com关于Candel治疗(CADL)的研究报告
- 对塔吉特来说,最糟糕的时期可能已经过去,但这只股票买起来安全吗?
- 这些液态天然气股票准备好上行了吗?
- 内部人士正在买入的两只有趣的股票
- 诺华在避险市场中仍是一只冒险的股票
- 连续60年提高股息的3只防御性股票
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《秋茄治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Candel Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。